In contrast, lapatinib, another TKI used to treat advanced HER2-positive breast cancer without causing HTN as a side effect, showed an insignificant effect on EC viability and the levels of LEENE, eNOS, and VCAM1 RNA in vitro and ex vivo. This evidence concerns the gene NOS3 and breast cancer.